(Q37929647)

25 August 2017

title

Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic (English)

1 reference

25 August 2017

1 reference

3

M Elaine Husni

1 reference

25 August 2017

5

Abrar A Qureshi

1 reference

25 August 2017

Nicole F Velez

1

1 reference

25 August 2017

Erin X Wei-Passanese

series ordinal

2

1 reference

25 August 2017

Elinor A Mody

series ordinal

4

1 reference

25 August 2017

publication date

1 January 2012

1 reference

Archives of Dermatological Research

25 August 2017

published in

1 reference

25 August 2017

volume

304

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

7-13

1 reference

Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

The delivery of evidence-based preventive care for older Americans with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Epidemiology of psoriatic arthritis in the population of the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

The prevalence of psoriatic arthritis in people with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Economic burden of comorbidities in patients with psoriasis is substantial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Obesity in early adulthood as a risk factor for psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-011-1172-6

10.1007/S00403-011-1172-6

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference